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Abstract Effects of sulfatide and its precursor galactosylcer-
amide (gal-cer) on the kinetics of production of cytokines were
studied. In human mononuclear leucocytes, gal-cer but not
sulfatide induced significantly increased amounts of interleukin
(IL)-1L, IL-6 and tumor necrosis factor (TNF) mRNA. In
phytohemagglutinin-stimulated cultures, gal-cer increased the
levels of IL-1L and IL-6 mRNA and secreted IL-1L and IL-6,
while sulfatide decreased the amounts of IL-6 mRNA and
secreted IL-6. Gal-cer also increased TNF secretion. In
lipopolysaccharide-stimulated cells, sulfatide but not gal-cer
decreased the secretion of IL-1L and IL-10, a potent suppressor
of production of many cytokines. Thus, sulfatide and gal-cer
affect cytokine production differently, most likely at the level of
gene expression. This may have implications in diseases where
inflammatory cytokines play a pathogenic role.
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1. Introduction
The e¡ector and regulatory functions of mononuclear leu-
cocytes (MNCs) are to a large extent related to their capacity
to secrete in£ammatory cytokines such as interleukin (IL)-1L,
tumor necrosis factor (TNF) and IL-6 and anti-in£ammatory
cytokines such as IL-10. In in£amed tissues, an array of mol-
ecules induces cytokine secretion from MNCs. However,
apart from cytokines themselves, little is known of other cy-
tokine-modulating molecules expressed by tissues undergoing
pathologic alterations.
Glycolipids are ubiquitous structural components of the
lipid bilayer in most eukaryote biomembranes [1,2]. Sulfatide
(galactosylceramide (gal-cer)-3-O-sulfate) is physiologically
found in relatively large amounts in central and peripheral
nervous tissues, mainly in connection with myelin [3]. Sulfa-
tide is also expressed in pancreatic islets of Langerhans and in
speci¢c areas in the kidney, the choroid layer of the eye, the
ovum and circulating granulocytes [4^6]. The immediate met-
abolic precursor of sulfatide, gal-cer, is also found in myelin
and in the islets of Langerhans in amounts similar to sulfatide
[2]. In myelin sheets, sulfatide and gal-cer are important in
maintaining the integrity of the sheets, but other possible roles
of sulfatide and gal-cer are largely unknown [2,7].
Sulfatide is a ligand for the adhesion molecule L-selectin
and has reported to be involved in intercellular signalling
through increased levels of cytosolic free calcium in human
neutrophils and monocytes [8,9]. Sulfatide and gal-cer have
been reported to in£uence the production of several cytokines
thought to be involved in in£ammatory disease processes [8^
10], whereas GM1 is a ganglioside (sialic acid-containing gly-
cosphingolipid) with a mild immunosuppressive activity when
tested on the T-lymphocyte function [11,12].
In a previous in vitro study, we found that exogenously
added sulfatide and gal-cer a¡ected cytokine secretion from
phytohemagglutinin (PHA)- and lipopolysaccharide (LPS)-
stimulated MNCs [10]. The aim of this study was to further
elucidate the e¡ects of sulfatide and gal-cer on the in vitro
production of both pro- and anti-in£ammatory cytokines.
2. Materials and methods
2.1. Isolation and characterization of sulfatide, gal-cer and GM1
The monosialoganglioside GM1 served as a negatively charged gly-
cosphingolipid control. Sulfatide, gal-cer and GM1 were isolated by
high performance liquid chromatography from bovine brain as pre-
viously described and their purity was controlled by mass spectrom-
etry [13]. Endotoxin was measured by a limulus amebocyte lysate
(LAL) assay (QCL-1000, Bio-Whittaker, Walkersville, MD, USA).
2.2. Acid treatment of sulfatide
Removal of the sulfate group from sulfatide was performed as
follows. Sulfatide, 2 Wmol, was incubated with 2 ml 0.05 M H2SO4
for 20 h at room temperature. Addition of 1 ml 0.1 M NaOH stopped
the reaction and 4 ml chloroform was added for phase partition. The
lower phase was washed twice with methanol/water 1:1 (v/v). The
organic phase was evaporated under N2 and the acidic treatment
was repeated. After a second washing procedure, the gal-cer was iso-
lated as detailed elsewhere [13].
2.3. Cell cultures
MNCs from healthy adult blood donors were prepared by centri-
fugation of citrate blood bu¡y coats on Lymphoprep (Nycomed,
Oslo, Norway). The cells were cultured in RPMI 1640 (Biological
Industries, Kibbutz Beit Haemek, Israel) containing 2% fetal calf se-
rum (FCS) (HyClone, Logan, UT, USA) and 25 Wg/ml gentamicin
(ICN Flow, Irvine, UK). MNCs, 2U106 cells/ml, were incubated
with 30 WM gal-cer, GM1 or sulfatide, together with 0.1 Wg/ml LPS
(Escherichia coli 055:B5, Difco Laboratories, Detroit, USA) or 5 Wg/
ml PHA (Difco). After incubation, the supernatants were frozen at
320‡C and the cell pellets were kept at 380‡C for a maximum of
2 days before RNA extraction. The LAL assay did not reveal endo-
toxin contamination in the culture medium or the FCS.
2.4. Enzyme-linked immunosorbent assay (ELISA) for human
cytokines
IL-1L, IL-2, IL-6, IL-10 and TNF were measured by a double-
sandwich ELISA as described for IL-6 [14]. Brie£y, Immuno-Maxi-
sorb plates (Nunc, Roskilde, Denmark) were coated with protein-A
a⁄nity-puri¢ed unconjugated rabbit IgG raised against the puri¢ed
recombinant cytokines. Non-attached sites were blocked with 1% (v/v)
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human serum albumin (State Serum Institute, Copenhagen, Denmark)
and 4% (w/v) milk (Irma, RÖdovre, Denmark) in phosphate-bu¡ered
saline. Biotinylated polyclonal rabbit antibodies to the cytokines were
used for detection along with streptavidin-peroxidase (Kirkegaard and
Perry, Gaithersburg, MD, USA). 1,2-Phenylenediamine (DAKO,
Glostrup, Denmark) was used as substrate and the plates were read
at 492 nm. Inter- and intra-assay coe⁄cients of variations were below
10%. The sensitivity limit of the ELISAs was 10^15 pg/ml and the
concentration range for the assays was up to 2 ng/ml. The di¡erent
ELISAs were calibrated with the corresponding international stand-
ards (National Institute for Biological Standards and Controls, Pot-
ters bar, Hertfordshire, UK). The antibodies used in the ¢ve ELISAs
did not cross-react or detect a number of other human cytokines,
including recombinant IL-1K, IL-1 receptor antagonist and lympho-
toxin (also termed TNFL).
2.5. RNA puri¢cation and hybridization
RNA was puri¢ed from frozen cell pellets (107 cells per RNA prep-
aration) and hybridized as previously described [15]. RNA was sepa-
rated on 1% (w/v) agarose gels using glyoxal and acridine orange [16].
cDNA probes for IL-6 (TaqI/BanII insert), TNF (EcoRI insert), IL-1L
(EcoRI/PstI insert) and for the household gene GAPDH (PstI insert)
were isolated from plasmids. After hybridization, the membranes were
exposed to a Fuji imaging plate (type BAS-III) and scanned in a Fujix
bio-imaging analyzer BAS 2000 (Raytest Isotopenmessgera«te, Strau-
benhardt, Germany). Excitation was quantitated by densitometry
(Tina, Raytest). The amounts of IL-1L, IL-6 and TNF mRNA were
calculated relative to the amount of the corresponding GAPDH
mRNA.
3. Results
In the ¢rst series of experiments, we examined the dose
response of sulfatide, gal-cer and GM1 on the production of
cytokines by MNC. IL-1L, IL-6 and TNF mRNA were meas-
ured, together with the levels of secreted IL-1L, IL-2, IL-6,
TNF and IL-10. The glycolipids were tested at concentrations
from 0.1 WM to 300 WM on MNCs co-incubated with 0.1 Wg/
ml LPS or with 5 Wg/ml PHA. Generally, sulfatide, gal-cer and
GM1 did not substantially a¡ect cytokine mRNA production
or secretion below 10 WM (data not shown).
In the second series of experiments, we examined the time
course of co-stimulating LPS- or PHA-stimulated MNCs with
30 WM sulfatide, gal-cer and GM1.
3.1. E¡ect of glycolipids alone
As shown in Fig. 1, only small amounts of cytokine mRNA
were produced in MNCs when cultivated in medium alone, in
medium containing sulfatide or in medium containing GM1.
A minor increase in the level of TNF mRNA was seen with
prolonged incubation. An increased secretion of TNF, how-
ever, did not follow this.
In contrast, signi¢cantly increased amounts of IL-1L, IL-6
and TNF mRNA were found in cells from cultures containing
gal-cer. In cultures containing sulfatide, the production of
IL-6 mRNA was slightly but not signi¢cantly reduced com-
pared to IL-6 mRNA production from MNCs cultured in
medium alone.
Fig. 1. Cytokine mRNA production. MNCs were cultivated in me-
dium alone (a, dashed lines) or in medium with 30 WM of each of
the glycolipids: sulfatide (F), gal-cer (b) and GM1 (a). Data are
shown as percentages of LPS controls þ S.E.M., n = 5. * P = 0.04,
** P = 0.02; the Mann-Whitney rank sum test.
Fig. 2. PHA-induced IL-1L mRNA/protein production. E¡ects of
sulfatide and gal-cer on IL-1L mRNA production (upper panel) and
IL-1L secretion (lower panel). MNCs were cultivated with 5 Wg/ml
PHA and 30 WM glycolipid. Symbols are as in Fig. 1. Data are
shown as percentages of PHA controls þ S.E.M., n = 4 (upper panel)
and as pg IL-1L/ml þ S.E.M., n = 4 (lower panel). The broken line
shows the PHA control.
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3.2. E¡ect on PHA-stimulated MNCs
PHA primarily functions as a non-speci¢c activator of T-
lymphocytes. Accordingly, PHA is only a weak inducer of the
cytokines IL-1L and IL-6, which in MNCs cultures are pri-
marily derived from the monocytes/macrophages (see legends
to Figs. 2 and 3).
As shown in Fig. 2, both gal-cer and sulfatide increased the
amount of stimulated IL-1L mRNA. However, gal-cer accel-
erated the formation of PHA-induced IL-1L mRNA com-
pared with sulfatide. While only small amounts of IL-1L
were secreted from MNCs stimulated with PHA alone and
co-stimulation with sulfatide failed to release cytokines at
measurable levels, co-stimulation with gal-cer increased the
amounts of IL-1L in the supernatants.
As shown in Fig. 3, sulfatide initially decreased the amounts
of IL-6 mRNA and secreted IL-6 from PHA-stimulated
MNCs. GM1 had a similar e¡ect. In contrast, gal-cer substan-
tially increased the amounts of IL-6 mRNA and secreted IL-6.
In PHA-stimulated MNCs, sulfatide induced a minor increase
in the secretion of IL-2 and a decrease in IL-10. GM1, but not
gal-cer, had similar e¡ects (not shown). IL-2 and IL-10
mRNA levels were not examined.
3.3. E¡ect on LPS-stimulated MNCs
LPS is a strong stimulator of monocyte/macrophage-de-
rived IL-1L, IL-6 and TNF with a limited e¡ect on T-lym-
phocyte-derived cytokines, such as IL-2. Hence, LPS induced
10 times more IL-6 mRNA and had a 6-fold stronger e¡ect on
IL-1L mRNA production than PHA (not shown). The
amounts of secreted IL-1L, IL-6, TNF and IL-10 were also
substantially increased compared to those released in response
to PHA (not shown).
As shown in Fig. 4, co-incubation with sulfatide decreased
the LPS-stimulated secretion of IL-1L and IL-10, while gal-cer
increased the secretion of IL-1L, but not IL-10. GM1 inhib-
ited the secretion of TNF.
3.4. Endotoxin (LPS) contamination of gal-cer
While the sulfatide and GM1 preparations contained less
than 6 pg LPS/Wmol, a LAL assay revealed a slight endotoxin
contamination of the gal-cer preparation: 70 pg LPS/Wmol
gal-cer, resulting in LPS levels in the cell cultures up to 2 pg/
ml. This, however, did not in£uence the cytokine mRNA in-
duction or cytokine secretion (data not shown). To further
examine whether the slight LPS contamination underlined
the di¡erent e¡ects of sulfatide and gal-cer on cytokine pro-
duction, sulfatide was treated with acid. This removes the
sulfate group and thus generates gal-cer and acid treatment
does not a¡ect LPS. As expected, acid-treated sulfatide, con-
taining 50 pg LPS/Wmol gal-cer, had the same e¡ect on IL-6
mRNA production and IL-6 secretion as native gal-cer.
Fig. 3. PHA-induced IL-6 mRNA/protein production. E¡ects of sul-
fatide and gal-cer on IL-6 mRNA production (upper panel) and
IL-6 secretion (lower panel). Data are shown as percentages of
PHA controls þ S.E.M., n = 4 (upper panel) and as pg IL-6/
ml þ S.E.M., n = 4 (lower panel). The broken line shows the PHA
control. See legend to Figs. 1 and 2.
Fig. 4. LPS-induced cytokine production. MNCs were cultivated
with 30 WM glycolipid and 0.1 Wg/ml LPS. Data are shown as pg/
ml þ S.E.M., n = 4. The broken line shows the LPS control. Symbols
are as in Fig. 1.
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4. Discussion
Sulfatide alone failed to a¡ect IL-1L or TNF mRNA but
reduced the expression of IL-6 mRNA relative to its expres-
sion in MNCs cultured in medium alone. In contrast, gal-cer
alone signi¢cantly enhanced the expression of IL-1L, TNF
and IL-6 mRNA in MNCs. Thus, the cytokine modulatory
e¡ects of sulfatide and gal-cer are dependent on sulfation of
the galactose ring. We could not con¢rm the pattern of cyto-
kine release reported by Constantin et al. [9], most likely
because Constantin et al. used 4^15 times higher levels of
sulfatide to show signi¢cant e¡ects on TNF, IL-1L and
IL-6. Sulfatide forms micelles in aqueous solutions, the sizes
of which are dependent on the sulfatide concentration.
While PHA primarily stimulates T-lymphocytes to cytokine
production, LPS, one of the principal envelope components of
Gram-negative bacteria, stimulates cytokine production in
monocytes/macrophages [17,18]. The most prominent ¢ndings
in the case of PHA stimulation were the substantial secretion
of IL-1L induced by gal-cer and the di¡erent e¡ects on IL-6
mRNA production and IL-6 secretion induced by sulfatide
and gal-cer. The di¡erent e¡ects of sulfatide and gal-cer on
cytokine production are unlikely due to endotoxin contami-
nation. Sulfatide and gal-cer were isolated from bovine brain
using a similar chromatographic equipment and separation
steps. Furthermore, acid-treated sulfatide (i.e. gal-cer) had
the same e¡ect on IL-6 mRNA production and IL-6 secretion
as native gal-cer. Gal-cer, while strongly inducing IL-1L, IL-6
and TNF in PHA-stimulated MNCs, did not modulate the
production of IL-10 or IL-2. Since IL-10 is induced by LPS,
one would expect an increased production of IL-10 if the
e¡ects of gal-cer were due to endotoxin contamination. The
concentrations of LPS in cultures were always less than 2 pg/
ml and at least 10-fold lower than the threshold level capable
of activating MNC cytokine production (unpublished ¢nd-
ings). The structural di¡erence alone is therefore likely to
account for the observed di¡erent e¡ects of sulfatide and
gal-cer on cytokine production.
Sulfatide and gal-cer appear to a¡ect the PHA-induced cy-
tokine production at the level of gene expression. Thus, the
induction of IL-1L and IL-6 secretion from MNCs stimulated
with PHA and gal-cer followed an increased production of IL-
L and IL-6 mRNA. Sulfatide decreased the secretion of IL-6
and modulated the secretion of TNF from MNCs stimulated
with PHA after similar changes in the mRNA levels. Finally,
a minor increase in production of TNF mRNA was followed
by a substantial increase of TNF secretion in MNCs co-in-
cubated with PHA and gal-cer. In contrast, gal-cer and sulfa-
tide modulated the secretion of IL-1L from LPS-stimulated
cells without a¡ecting the mRNA level. IL-1L, together with
its close relative IL-1K, di¡ers from most other cytokines by
the lack of a signal sequence. This results in dissociation of
synthesis and secretion of the cytokine and processing of the
immature pro-IL-1L are thought to be subject to multiple
levels of regulation [19^22]. Secretion of IL-1L is regulated
di¡erentially in di¡erent cell types and in monocytes/macro-
phages, IL-1L secretion occurs without preceding gene expres-
sion [20,21].
After challenge with LPS, MNCs produce and secrete in-
£ammatory cytokines such as IL-1L, IL-6 and TNF [19,23,24].
Though less abundantly, these cytokines are also produced by
activated T-lymphocytes and, secondary, after T-lymphocyte
activation of monocytes/macrophages in MNC cultures. The
substantial increase in IL-1L, IL-6 and TNF production and
secretion from PHA-stimulated MNCs challenged with gal-cer
is likely to originate primarily from activation of T-lympho-
cytes. Whether sulfatide suppresses cytokine production and
secretion primarily through T-lymphocytes cannot be eluci-
dated from this study. The e¡ects of the glycolipids were
seen most clearly when co-cultivated with PHA and often,
the e¡ects on the mRNA or the secreted cytokine from
MNCs stimulated with LPS alone could not be distinguished
from those with added glycolipid. It is possible that LPS in-
duces near maximum production of cytokines and that addi-
tive e¡ects of glycolipids are di⁄cult to measure.
It is potentially interesting that gal-cer increases production
of cytokines that are cytotoxic to islet L-cells [25]. For exam-
ple, gal-cer enhanced IL-1L mRNA production by PHA-
stimulated MNCs and this was followed by an intensi¢ed
secretion of IL-1L at levels up to 10 000 pg/ml after 48 h.
Since sulfatide and gal-cer are present in the islets of Langer-
hans and their expression is regulated by glucose [26], stressed
L-cells might stimulate local in¢ltrating leucocytes to produce
potentially L-cell-damaging mediators, including IL-1L.
Acknowledgements: The skilful technical assistance of A. AmbjÖrnsen
and B.-M. Rynmark is highly appreciated. The plasmids were kind
gifts from T. Hirano (IL-6), A. Singh (TNF), S. Gillis (IL-1L) and
J. Skouv (GAPDH). The Danish Biotechnology Programme and the
Swedish Medical Research Council (Grants K99-03x-09909-08C) sup-
ported the study.
References
[1] Hakomori, S. (1990) J. Biol. Chem. 265, 18713^18716.
[2] Vos, J.P., Lopes-Cardozo, M. and Gadella, B.M. (1994) Biochim.
Biophys. Acta 1211, 125^149.
[3] Svennerholm, L., Bostro«m, K., Fredman, P., Jungbjer, B., Mafin-
sson, J.-E. and Rynmark, B.-M. (1992) Biochim. Biophys. Acta
1128, 1^7.
[4] Buschard, K., Josefsen, K., Horn, T. and Fredman, P. (1993)
Lancet 342, 840.
[5] Buschard, K., Josefsen, K., Hansen, S.V., Horn, T., Marshall,
M.O., Persson, H., Mafinsson, J.-E. and Fredman, P. (1994) Dia-
betologia 37, 1000^1006.
[6] Buschard, K., Horn, T., Aaen, K., Josefsen, K., Persson, H. and
Fredman, P. (1996) Diabetologia 39, 658^666.
[7] Winter, J., Mirsky, R. and Kadlubowski, M. (1982) J. Neuro-
cytol. 11, 351^362.
[8] Laudanna, C. et al. (1994) J. Biol. Chem. 269, 4021^4026.
[9] Constantin, G., Laudanna, C., Baron, P. and Berton, G. (1994)
FEBS Lett. 350, 66^70.
[10] Buschard, K., Diamant, M., Bovin, L.F., Mafinsson, J.-E., Fred-
man, P. and Bendtzen, K. (1996) APMIS 104, 938^944.
[11] Ladisch, S., Ulsh, L., Gillard, B. and Wong, C. (1984) J. Clin.
Invest. 74, 2074^2081.
[12] Ladisch, S., Becker, H. and Ulsh, L. (1992) Biochim. Biophys.
Acta 1125, 180^188.
[13] Mafinsson, J.E., Mo, H.Q., Egge, H. and Svennerholm, L. (1986)
FEBS Lett. 196, 259^262.
[14] Hansen, M.B., Svenson, M., Diamant, M. and Bendtzen, K.
(1991) Scand. J. Immunol. 33, 777^781.
[15] Rieneck, K., Diamant, M., Haahr, P.-M., Scho«nharting, M. and
Bendtzen, K. (1993) Immunol. Lett. 37, 131^138.
[16] McMaster, G.K. and Carmichael, G.G. (1977) Proc. Natl. Acad.
Sci. USA 74, 4835^4838.
[17] Heegaard, P.M.H. and Mu«ller, K. (1988) J. Immunol. Immuno-
pharmacol. 8, 239^247.
[18] Osterud, B., Olsen, J.O. and Wilsgard, L. (1990) Adv. Exp. Med.
Biol. 256, 389^398.
FEBS 22358 16-7-99
L.F. Bovin et al./FEBS Letters 455 (1999) 339^343342
[19] Dinarello, C.A. (1991) Blood 77, 1627^1652.
[20] Siders, W.M. and Mizel, S.B. (1995) J. Biol. Chem. 270, 16258^
16264.
[21] Wingren, A.G. et al. (1996) Cell Immunol. 169, 226^237.
[22] Egan, P.J. and Nash, A.D. (1996) Vet. Immunol. Immunopathol.
55, 163^174.
[23] Akira, S., Hirano, T., Taga, T. and Kishimoto, T. (1990) FASEB
J. 4, 2860^2867.
[24] Bendtzen, K. (1994) Immunol. Lett. 43, 111^123.
[25] Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J.H.,
Dinarello, C.A. and Svenson, M. (1986) Science 232, 1545^
1547.
[26] Aaen, K., Rygaard, J., Josefsen, K., Petersen, H., Brogren, C.H.,
Horn, T. and Buschard, K. (1990) Diabetes 39, 697^701.
FEBS 22358 16-7-99
L.F. Bovin et al./FEBS Letters 455 (1999) 339^343 343
